Mangiferin Induces Post-Implant Osteointegration in Male Diabetic Rats

Area of Science:

• Biomaterials Science
• Endocrinology
• Regenerative Medicine

Background:

• Hyperglycemia associated with type-II diabetes impairs implant osteointegration.
• Mangiferin (MF), a natural compound, was investigated for its potential to mitigate these negative effects.
• Understanding the molecular and morphological impacts of MF on bone healing in diabetes is crucial.

Purpose of the Study:

• To investigate the effects of mangiferin (MF) on the osteointegration process in a type-II diabetes rat model.
• To evaluate the molecular and morphological changes associated with MF administration.
• To determine MF's potential as a therapeutic agent for impaired bone healing in diabetic patients.

Main Methods:

• Sprague Dawley rats were divided into control, diabetes, and diabetes + MF groups, with tibial implants placed.
• Blood samples were analyzed for biochemical markers; tibia samples underwent micro-CT, qRT-PCR, histological, and immunohistochemical analyses.
• A 3-month experimental period allowed for comprehensive assessment of osteointegration and bone repair.

Main Results:

• MF administration significantly improved glycemic control, lipid profiles, and liver enzymes in diabetic rats.
• MF treatment increased osteointegration percentage, bone volume, and expressions of key bone-related genes (DKK1, BMP-2, OPN, OCN, OSN).
• Histological analysis showed increased osteoblast activity and decreased osteoclast activity in MF-treated diabetic rats.

Conclusions:

• Mangiferin demonstrates significant potential to improve implant osteointegration in the context of type-II diabetes.
• MF positively influences bone regeneration by modulating key molecular pathways and cellular activities.
• These findings suggest MF as a promising therapeutic strategy for enhancing bone repair in diabetic individuals.